Myokardia at inflection point as heart drug readout nears

MyoKardia is headed for its biggest moment since debuting as a publicly traded company in 2015. Forthcoming results from a Phase 3 study of its heart disease treatment mavacamten will be an inflection point, as the California-based biotech will either have a drug ready to submit for an approval, or will be contemplating several more years of unprofitable clinical development.